A new study published in the New England Journal of Medicine demonstrates a stunning lack of understanding of the 340B drug pricing program and the overall landscape of drug pricing.
340B Drug Pricing Program Blogs
Latest
With only 11 days that the House and Senate are in session together before the fiscal year concludes, much of the attention in Washington is on how Congress will fund the government and whether there will be a government shutdown.
Modern Healthcare’s putative report on CMS’ 340B remedy proposal is completely wrong and irresponsible for the following reasons. First, to buttress its conclusions the article relies on quotes from an academic whose 340B research is funded in whole or in part by an organization with an anti-hospital agenda.
A new opinion piece supported by Arnold Ventures and published in the New England Journal of Medicine is another unfair assault on the only sector in health care that routinely gives back so much more to their communities than they receive in tax relief.
Once again, the Pharmaceutical Research and Manufacturers of America (PhRMA) has demonstrated its willingness to put the profits of its drug company members over the needs of America’s patients.
The convening of the 118th Congress this week is a reminder of Washington’s highly-charged political environment.
Forty-six days from now on Nov. 8 millions of Americans will cast their ballots and exercise their most sacred right – the right to vote.
In July, the Centers for Medicare & Medicaid Services published its annual outpatient prospective payment system regulation.
With a few hours to digest this morning’s oral argument in American Hospital Association v. Becerra, I wanted provide a few high-level reactions.
The Supreme Court of the United States Nov. 30 will hear oral arguments in a case brought by the AHA and others asking the court to reverse the 2020 federal appeals court decision that upheld the authority of the Department of Health and Human Services to significantly cut payments to certain hospitals that participate in the 340B Drug Pricing Program, threatening access care for patients.
A new report from the Community Oncology Alliance (COA) once again tries to obfuscate the issue of sky-rocketing drug prices by choosing to blame hospitals rather than the drug companies who set the prices and enjoy double-digit profits at the expense of patients and the providers who serve them.
America’s hospitals and health systems, and our heroic caregivers, have been on the front lines of the battle against COVID-19 for the past year, working tirelessly to provide needed care to patients and communities.
The pharmaceutical industry’s latest “report” is an obvious attempt to divert attention away from a problem of their own making: skyrocketing drug prices.
The latest report from AIR340B continues to misrepresent a program with a more than 25-year history of helping hospitals stretch scarce financial resources to expand and improve access to lifesaving prescription drugs and comprehensive health services for the many patients served by participating hospitals.
We’re 11 days into 2019 … we’ve returned to a divided government …and the partial government shutdown continues.
As the industry “that generates higher profit margins than any other,” Big Pharma continues to price gouge consumers for life-saving drugs. One thing the pharmaceutical industry is not entitled to, however, is its own set of facts.
A recent article in the New York Times, “A Little-Known Windfall for Some Hospitals, Now Facing Big Cuts,” gives a thoroughly inaccurate and misleading view of the 340B Drug Pricing Program.
Another week, another drug industry-funded consultant attempting to divert attention away from the high and rising costs of prescription drugs by attacking the 340B drug pricing program.
The U.S. health care system is facing a prescription drug spending crisis fueled by staggering increases in recent years in the price of drugs.
A recent study published in the New England Journal of Medicine on the 340B program includes a number of methodological flaws that invalidate the findings, including one major flaw: how the authors ignored a significant data source in drawing their conclusions.